Circulating heregulin level is associated with the efficacy of patritumab combined with erlotinib in patients with non-small cell lung cancer

Kimio Yonesaka,Kenji Hirotani,Joachim von Pawel,Mircea Dediu,Shuquan Chen,Catherine Copigneaux,Kazuhiko Nakagawa

Lung Cancer（2017）

引用 20|浏览19

暂无评分

摘要

•Patritumab plus erlotinib did not improved PFS compared with placebo plus erlotinib in NSCLC.•Soluble heregulin highly expressed in serum from subgroup of NSCLC patients.•Patritumab plus erlotinib significantly improved PFS in a soluble heregulin-high subgroup.

查看译文

关键词

HER3,NSCLC,HRG,EGFR,ITT,qRT-PCR

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要